The anti-mycoplasmal activity of aminosidine.

Some in vivo experiments of therapeutic activity in severe experimental infection (intracranial) in the mouse due to different strains of Mycoplasma proved the high efficacy of the antibiotic aminosidine when administered subcutaneously at the dose of 30 mg/kg and have also demonstrated that oral treatment is moderately effective against Mycoplasma hominis 2. Sensitivity test carried out in vitro on the same Mycoplasma strains confirmed the bactericidal activity of aminosidine. These experiments have therefore shown that the therapeutic spectrum of aminosidine, which includes Gram-positive, Gram-negative, acid-fast bacteria and some protozoa, may be enlarged to include the genus Mycoplasma. For this reason the antibiotic can find a useful application in the treatment of primary atypical neumonia. In addition, from a clinical research point of view, aminosidine may constitute a promising tool for the treatment of different illnesses in which Mycoplasma have been described as important co-factors of pathogenicity in man.